Revenue (Tables)

9 Months Ended

Sep. 30, 2021

Disaggregation of Revenue [Abstract]

Disaggregation of Revenue [Table Text Block]

The following tables disaggregate our revenue from contracts with customers by business and geographic region (in millions):

	Three Months Ended September 30,
	2021						2020
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	306	$	227	$	533	$	270	$	205	$	475
Urology and Pelvic Health	275		109		384		251		99		350
Cardiac Rhythm Management	312		199		512		275		190		465
Electrophysiology	32		55		86		33		43		76
Neuromodulation	175		46		221		176		41		216
Interventional Cardiology	376		368		744		255		331		586
Peripheral Interventions	250		202		452		236		179		416
Specialty Pharmaceuticals	—		—		—		65		10		74
Net Sales	$	1,726	$	1,206	$	2,932	$	1,560	$	1,098	$	2,659

On March 1, 2021, we completed the divestiture of the Specialty Pharmaceuticals business. Our consolidated net sales for the first nine months of 2021 include Specialty Pharmaceuticals up to the date of the closing of the transaction.

	Nine Months Ended September 30,
	2021						2020
Businesses	U.S.		Int'l		Total		U.S.		Int'l		Total
Endoscopy	$	902	$	681	$	1,583	$	715	$	550	$	1,265
Urology and Pelvic Health	817		325		1,142		650		260		910
Cardiac Rhythm Management	903		603		1,505		738		515		1,253
Electrophysiology	96		169		265		86		116		202
Neuromodulation	520		145		666		426		103		529
Interventional Cardiology	1,117		1,113		2,230		741		973		1,714
Peripheral Interventions	748		609		1,358		649		499		1,148
Specialty Pharmaceuticals	10		4		13		162		21		183
Net Sales	$	5,112	$	3,649	$	8,761	$	4,167	$	3,037	$	7,204

	Three Months Ended September 30,				Nine Months Ended September 30,
Geographic Regions	2021		2020		2021		2020
U.S.	$	1,726	$	1,496	$	5,103	$	4,005
EMEA (Europe, Middle East and Africa)	590		540		1,855		1,507
APAC (Asia-Pacific)	517		472		1,511		1,292
LACA (Latin America and Canada)	99		77		279		217
Medical Devices	2,932		2,584		8,748		7,021
U.S.	—		65		10		162
International	—		10		4		21
Specialty Pharmaceuticals	—		74		13		183
Net Sales	$	2,932	$	2,659	$	8,761	$	7,204
Emerging Markets(1)	$	354	$	291	$	1,030	$	832

(1)    We define Emerging Markets as the 20 countries that we believe have strong growth potential based on their economic conditions, healthcare sectors and our global capabilities. Periodically, we assess our list of Emerging Markets countries, and effective January 1, 2021, modified our list to include the following countries: Brazil, Chile, China, Colombia, Czech Republic, India, Indonesia, Malaysia, Mexico, Philippines, Poland, Russia, Saudi Arabia, Slovakia, South Africa, South Korea, Taiwan, Thailand, Turkey and Vietnam. We have revised prior period amounts to conform to the current year's presentation which had an immaterial impact on previously reported Emerging Markets net sales.